Collection of Bone Marrow, Peripheral Blood (PB), Epithelial Tissue, and Saliva Samples From Patients With Myelodysplastic Syndromes (MDS) to Identify MDS-Specific Antigens (MSA) for Use in Cellular Immunotherapy.
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Myelodysplastic Syndromes(MDS)
- Sponsor
- PersImmune, Inc
- Enrollment
- 24
- Locations
- 2
- Primary Endpoint
- Genomics of patients with MDS
- Last Updated
- 7 years ago
Overview
Brief Summary
The purpose of this study is to collect information and bone marrow, blood, saliva, cheek cells and skin to be used in the laboratory to assist the sponsor in identifying a new way of treating MDS.
Detailed Description
Goals of the study: The purpose of this study is to collect the blood and marrow samples, and non-involved fibroblasts, that are required to identify the unique, personalized array of mutation-driven neoantigens that are expressed by the subject's MDS cells and to assess the feasibility of immunizing and expanding one or more of the patient's T cells ex vivo for investigation of their use as adoptive cellular immunotherapy.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Genomics of patients with MDS
Time Frame: 2 years
To sequence the exome and transcriptome obtained from MDS hematopoietic cells and the exome from non-hematopoietic cells (e.g. fibroblasts).
Secondary Outcomes
- Identification of patients' MDS-specific variant(2 years)
- Immunogenic mutant neoantigen peptide selection(2 years)
- Data analysis and interpretation(2 years)
- Peptide Immunogenicity confirmation and donor T cell stimulation(2 years)
- Peptide immunogenicity confirmation and donor T cell stimulation(2 years)